Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples